Oct 20 (Reuters) – The U.S. Food and Drug Administration
approved GlaxoSmithKline’s Shingrix shingles vaccine for
use in adults aged 50 and over, a move widely expected after an
advisory panel to the agency last month voted unanimously to
recommend its approval, the company announced on Friday.

Read More At Article Source | Article Attribution